MAP Pharmaceuticals, Inc., (MAP) is a development stage company, engaged in developing drug candidates to treat local respiratory and treatable diseases. The company also develops inhalable drug particles to facilitate pulmonary delivery. The company’s proprietary product candidate is Unit Dose Budesonide, a nebulized version of budesonide for the treatment of pediatric asthma in children. The company is headquartered at Mountain View in California, United States
MAP Pharmaceuticals – Pharmaceuticals & Healthcare – Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.
Scope
- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
To know more about this report kindly visit:
http://www.aarkstore.com/reports/MAP-Pharmaceuticals-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-20639.html
No comments:
Post a Comment